Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The PALETTE randomized phase III trial has reported a statistically significant benefit for the use of pazopanib compared to placebo in terms of progression-free survival for the treatment of soft-tissue sarcoma. However, no benefit in terms of overall survival was observed, the reasons for which might lie in the study design.
Life expectancy of most patients with differentiated thyroid cancer is normal, so adverse treatment effects should be minimized. Lower activities of radioiodine for ablation of thyroid remnants are non-inferior to higher activities and quality of life can be maintained by preparation of radioiodine remnant ablation using recombinant human thyrotropin.
Treatment of locally advanced non-small-cell lung cancer (NSCLC) in the elderly is challenging, with many available treatment options from radiotherapy alone to sequential chemoradiation. The latest phase III trial comparing radiotherapy alone with concurrent chemoradiation reported a survival improvement for the combination; however, this does not define a new standard treatment.
Venous thromboembolism (VTE) is a potentially life-threatening condition that can be associated with significant morbidity and is linked to cancer by numerous pathophysiological mechanisms. Here, the risk factors, mechanisms, prevention, and optimal treatment of VTE in patients with cancer are discussed.
Hodgkin lymphoma has become one of the most successfully treatable cancers; nevertheless, adverse treatment-related side effects still occur. In this Review, Borchmann et al. discuss the current choices for patients with Hodgkin lymphoma by finding the balance between optimal disease control and the risk of long-term sequelae.
Breast cancers in young women are typically aggressive and so young age can correlate with a poorer outcome. In this Review article, Steven Narod discusses the risk factors, risks of recurrence and secondary cancer, treatment, prevention and awareness of very-early onset breast cancer.
A multidisciplinary colloquium—Developing Strategies for Reducing Cancer Treatment-Related Toxicities and Symptoms—was held to identify the challenges that have prevented progress in reducing cancer-treatment-related symptom burden and to develop strategic steps to meet these challenges. This Perspectives article summarizes the recommendations of the panel, and includes suggestions for improving cancer care in the clinic and developing a policy and advocacy strategy to expand research on toxicity.
The use of tumour molecular profiles for therapeutic decision making requires that molecular diagnostics be introduced into routine clinical practice. To this end, the French National Cancer Institute and French Ministry of Health have set up a national network of 28 regional molecular genetics centres. In this Perspectives article, the authors look at the 4-year history of the French initiative and discuss its success in rapidly implementing molecular tests for new tumour biomarkers.